| *Sponsored by Nutriband Inc.
(Nasdaq: NTRB) Is Now Above 3 Key Chart Technical Levels (Low Float Idea Continues In The Green)
February 13th Greetings, Friend!
(Nasdaq: NTRB) moved into interesting chart positioning early Thursday.
After pushing above its 13-Day Exponential Moving Average (EMA) this morning, NTRB is now trading above 3 key technical levels including its 50-Day Simple Moving Average (SMA) and its 200-Day SMA.
Could support potentially start growing at those levels creating the building blocks for NTRB to return to previous highs?
Don't forget. The company announced major news today: Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fent-a-nyl Abuse Deterrent Fent-a-nyl Patch.
Furthermore, Barchart continues reporting at least 10 triggered technical indicators on its website with their "Trend Seeker" composite indicator being triggered as well for NTRB.
(Nasdaq: NTRB) continues to climb up my watchlist Thursday. Consider it for yours and read my initial report below. -----
It's a short time until Thursday's opening bell, so let me be brief.
We've started putting together a little bit of a breakout streak.
Most recently, my last profile, an NYSE American idea, surged approximately 15% from a previous night's after-hours close of $1.30 to following day high of $1.50
Prior to that, we saw a profile last week pop almost $2.00 while running approx. 29%.
Now, it's time to gather our focus once again for a breakout idea oozing with potential. Here's what to consider right now:
#1. This is a low float idea with fewer than 6Mn shares in its float. Volatility potential could be high.
#2. At close Wednesday, there were several triggered technical indicators being reported for this profile over at Barchart.
#3. In January, this Nasdaq idea was tagged with a $13 analyst target. From its closing valuation Wednesday, that target suggests a potential upside of over 80%.
That and more is why Nutriband Inc. (Nasdaq: NTRB) is a pharmaceutical company climbing my watchlist early in 2025.
Why? Part of its due to its innovative approach to transdermal drug delivery and its potential to revolutionize patient care, particularly in the field of pain management and abuse prevention.
The company's primary focus is on developing a portfolio of transdermal pharmaceutical products, with its flagship product being an abuse-deterrent fent-a-nyl patch incorporating their proprietary AVERSA™ technology.
This technology is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, addressing a critical issue in the opioid crisis.
Nutriband's potential for growth and market impact is supported by several key factors:
#1. A Massive Analyst Target: In January, Noble Capital Markets analyst, Robert LeBoyer, tagged NTRB with a $13 target. From Wednesday's 4:00PM EST closing valuation, that target suggests over 80% potential upside.
#2. Important Patent News: Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™.
#3. Revenue Growth: One of the company's subsidiaries has shown significant revenue growth, with a record third quarter in 2024 reporting revenue of $645k+, up 50.94% year-over-year. This growth trend continued from previous years, with a 48% increase in revenue for Q2 2023 compared to Q2 2022.
#3. Market Potential: According to Health Advances' assessment, upon FDA approval, Aversa Fent-a-nyl is expected to reach peak annual sales of $200Mn. If non-abuse-deterrent formulations lose marketing approval, this could potentially increase to over $800Mn in revenue.
#5. Diverse Product Portfolio: Beyond AVERSA™, Nutriband is developing a range of transdermal products for pharmaceuticals with abuse risks and exploring applications for delivering biologics typically administered by injection.
#6. Strategic Partnerships and Distribution: Nutriband's products are being rolled out in prominent retail locations nationwide, including Target, Walmart, Walgreens, and CVS, indicating strong market penetration.
#7. Triggered Technical Indicators: At close on Wednesday, Barchart was reporting at least 8 triggered technical indicators across the short, medium, and long term.
#8. Manufacturing Capabilities: Nutriband owns its manufacturing and clinical development facilities, which significantly reduces costs for AVERSA™ and other technologies.
#9. Potential Upcoming Milestones: Nutriband is targeting an NDA submission for AVERSA™ Fent-a-nyl in the first half of 2025, which could be a significant catalyst for the company.
#10. Low Float: With just over 5Mn shares in its float, the profile has a low float, which could potentially lead to increased volatility in moments.
Nutriband's focus on addressing the opioid crisis through innovative drug delivery systems positions it at the intersection of two critical healthcare trends: the need for effective pain management and the imperative to prevent drug abuse.
The company's AVERSA™ technology has the potential to set a new safety standard for transdermal opioid medications, potentially saving countless lives.
Nutriband's diverse revenue streams from its subsidiaries, growing sales, and strong cash position provide a degree of stability as it pursues its ambitious goals.
As Nutriband approaches key milestones in 2025, particularly the planned NDA submission for AVERSA™ Fent-a-nyl, it represents an intriguing innovator of healthcare solutions with significant market potential.
Coverage is officially reinitiated on Nutriband Inc. (Nasdaq: NTRB). When updates are available, I'll be in touch.
All the best, Dane James Editor Market Pulse Today
Sources: NTRB Website NTRB Presentation
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, a single member limited liability company. Data is provided from third-party sources and MarketPulseToday is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired by TD Media LLC for a period beginning on 02/13/2025 and ending on 02/14/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”) to disseminate information about (NTRB:US) via digital communications. To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US).
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NTRB:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ntrb/#details | 
No comments:
Post a Comment